Campbell & Co Investment Adviser’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-8,318
| Closed | -$236K | – | 1172 |
|
|
2023
Q1 | $236K | Sell |
8,318
-14,229
| -63% | -$404K | 0.04% | 686 |
|
|
2022
Q4 | $659K | Sell |
22,547
-25,180
| -53% | -$736K | 0.16% | 209 |
|
|
2022
Q3 | $1.26M | Buy |
47,727
+42,840
| +877% | +$1.13M | 0.29% | 77 |
|
|
2022
Q2 | $217K | Sell |
4,887
-2,913
| -37% | -$129K | 0.06% | 582 |
|
|
2022
Q1 | $386K | Buy |
+7,800
| New | +$386K | 0.1% | 374 |
|
|
2019
Q1 | – | Sell |
-7,488
| Closed | -$334K | – | 635 |
|
|
2018
Q4 | $334K | Buy |
7,488
+2,488
| +50% | +$111K | 0.33% | 124 |
|
|
2018
Q3 | $347K | Buy |
+5,000
| New | +$347K | 0.24% | 164 |
|
|
2018
Q1 | – | Sell |
-4,218
| Closed | -$225K | – | 554 |
|
|
2017
Q4 | $225K | Buy |
+4,218
| New | +$225K | 0.17% | 285 |
|